The importance of apoptosis in cancer therapy has been demonstrated by numerous pre-clinical and clinical studies, and by the Food and Drug Administration approval of several small molecule inhibitors against anti-apoptotic proteins of the BCL2 family as therapeutic targets for certain cancer types [1]. This evidence concerns the gene BCL2 and cancer.